Sector News

Sobi appoints Norbert Oppitz SVP, speciality care

October 20, 2017
Life sciences

Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.

Oppitz has over 30 years’ pharmaceutical and healthcare experience and was most recently a member of the executive committee of BSN Medical in charge of its Latin America business.

In previous capacities, he has led organisations as head of Latin America at Takeda as well as in country management roles at Roche and Aventis Pharma.

He said: “I am excited to join Sobi and I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital speciality care business unit.”

The new role will see Oppitz work with corporate development and the regional and country organisations.

Guido Oelkers, president and CEO of Sobi, said: “We are delighted that Norbert could join Sobi, he is a true entrepreneur and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our speciality care business.”

Source: PMLive

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).